Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that activating PKM2 and Wnt/β-catenin signaling enhanced hair regrowth and hair follicle stem cell proliferation in mice, suggesting a potential alopecia treatment strategy.

This study suggests that autoimmune dysregulation involving HLA-DR+ T and NK cell subsets may contribute to severe patchy alopecia areata and alopecia universalis, with normalization seen after betamethasone treatment.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This review discusses the potential therapeutic effects of exosomes from various cell sources in treating acute kidney injury and explores their mechanisms, but reports no new clinical results.

This case study highlights the risks of ingesting topical minoxidil, demonstrated by a 24-year-old male who accidentally consumed 1500mg due to a language barrier, leading to a temporary rise in creatinine levels but no lasting kidney damage.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

This review explores the promising but varied effectiveness of tyrosine kinase inhibitors for treating different skin diseases, indicating their potential in dermatology while acknowledging the need for more evidence.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

This paper explores cell kinetics in human hair follicles, focusing on the proliferation rates of keratinocytes and dermal papilla cells, but provides no new experimental findings.

This study found that hair root sheaths can be accurately typed for erythrocyte acid phosphatase, adenylate kinase, and adenosine deaminase, consistent with blood typing results from the same donors.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

In this study, oral JAK inhibitors were found to be significantly more effective than placebo in promoting hair regrowth among adults and adolescents with moderate-to-severe alopecia areata, although they were associated with an increased risk of adverse events.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.

In this study, pediatric and young adults with alopecia areata reported high satisfaction with oral Janus kinase inhibitors, decreased hair loss severity, and a willingness to continue treatment despite potential risks, citing improvements in hair regrowth, tolerability, quality of life, and mental health.

JAK inhibitors are generally safe for treating alopecia areata.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

In this study, researchers using QM/MM simulations identified key molecular motions and residue interactions in the enzyme SRD5A2 that significantly influence its catalytic efficiency, demonstrating that specific residues play critical roles in stabilizing transition states and reducing activation barriers.

In this study, adults with significant alopecia areata were surveyed on their preferences for JAK inhibitor treatments, revealing a strong priority for scalp hair regrowth effectiveness and quicker initial regrowth over dosing convenience.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.